Effects of darbepoetin α on right and left ventricular systolic and diastolic function in anemic patients with chronic heart failure secondary to ischemic or idiopathic dilated cardiomyopathy

Parissis, John; Kourea, Kallirrhoe; Panou, Fotios; Farmakis, Dimitrios; Paraskevaidis, Ioannis; Ikonomidis, Ignatios; Filippatos, Gerasimos; Kremastinos, Dimitrios Th.

doi:10.1016/j.ahj.2008.01.016

Cited by 78 publications

(70 citation statements)

References 32 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…830 Two further studies confirmed these findings; however, none of these were double blind. 831,832 These positive data led to 2 larger studies. A 165-patient study showed that darbepoetin alfa was associated with improvement in several HRQOL measures with a trend toward improved exercise capacity (6-minute walking distance +34±7 m versus +11±10 m, P=0.074).…”

Section: Anemiamentioning

confidence: 99%

2013 ACCF/AHA Guideline for the Management of Heart Failure

et al. 2013

View full text Add to dashboard Cite

Section: Anemiamentioning

confidence: 99%

2013 ACCF/AHA Guideline for the Management of Heart Failure

et al. 2013

View full text Add to dashboard Cite

“…EPO, or its derivatives, the longer-acting darbepoetin (DA) or pegylated Mircera along with the addition of either oral or IV iron. Such treatment has been reported in uncontrolled studies [24,25,26,27,28], non-placebo-controlled studies [29,30,31], and small, single-blind [32,33,34,35] and double-blind [36,37], placebo-controlled studies or larger, double-blind, placebo-controlled studies [38,39,40]. The Hb increased by an average of about 2 g/dl with ESA treatment.…”

Section: The Effect Of Correction Of Anemia In Chf Patients Treated Wmentioning

confidence: 99%

“…In addition to the above findings, several of the studies have shown that correction of the anemia with ESA reduced diuretic dose, heart rate, plasma volume, left-ventricular hypertrophy and dilation, pulmonary artery pressure, the severity of mitral regurgitation, and inflammatory factors such as IL-6 and C-reactive protein, and improved renal function, caloric intake, depression, sleep apnea, left-ventricular diastolic function, and the adhesive and proliferative properties of circulating endothelial progenitor cells [24,25,26,27,28,29,30,31,32,33,34,35,36,37]. …”

Section: The Effect Of Correction Of Anemia In Chf Patients Treated Wmentioning

confidence: 99%

The Anemia of Heart Failure

Silverberg¹,

Wexler²,

Palazzuoli³

et al. 2009

Acta Haematol

View full text Add to dashboard Cite

Anemia is common in congestive heart failure (CHF) and is associated with an increased mortality and morbidity. The most likely causes of anemia are chronic kidney disease (CKD) and excessive cytokine production, both of which can cause depression of erythropoietin (EPO) production and bone marrow activity. The cytokines also induce iron deficiency by both reducing gastrointestinal iron absorption and iron release from iron stores located in the macrophages and hepatocytes. Iron deficiency can cause thrombocytosis which might also contribute to cardiovascular complications in both CHF and CKD and is partially reversible with iron treatment. Thus attempts to control this anemia will have to consider both the use of erythropoiesis-stimulating agents (ESA), such as EPO, as well as oral and, probably more importantly, intravenous (IV) iron. The many studies on anemia in CHF patients treated with ESA and oral or IV iron, and even with IV iron without ESA have up to now shown a quite consistent positive effect on hospitalization, fatigue, shortness of breath, quality of life, exercise capacity, and β-natriuretic peptide reduction, in the absence of increased cardiovascular damage related to the therapy. Adequately powered long-term placebo-controlled studies of ESA and/or IV iron are currently being carried out and their results are eagerly awaited.

show abstract

“…These protective effects may be due to a reduction of apoptosis in cardiac myocytes [99][100][101] and fibroblasts [99] . Other studies stated that in patients with congestive heart failure EPO improves ventricular performance and exercise capacity and reduces hospitalization rates [102][103][104] .…”

Section: Tissue-protective Effects Of Epomentioning

confidence: 99%

Erythropoietin: A Hormone with Multiple Functions

2011

View full text Add to dashboard Cite

Erythropoietin (EPO), the main hemopoietic hormone synthesized by the kidney as well as by the liver in fetal life, is implicated in mammalian erythropoiesis. Production and secretion of EPO and the expression of its receptor (EPO-R) are regulated by tissue oxygenation. EPO and EPO-R, expressed in several tissues, exert pleiotropic activities and have different effects on nonhemopoietic cells. EPO is a cytokine with antiapoptotic activity and plays a potential neuroprotective and cardioprotective role against ischemia. EPO is also involved in angiogenesis, neurogenesis, and the immune response. EPO can prevent metabolic alterations, neuronal and vascular degeneration, and inflammatory cell activation. Consequently, EPO may be of therapeutic use for a variety of disorders. Many tumors express EPO and/or EPO-R, but the action of EPO on tumor cells remains controversial. It has been suggested that EPO promotes the proliferation and survival of cancer cells expressing EPO-R. On the other hand, other reports have concluded that EPO-R plays no role in tumor progression. This review provides a detailed insight into the nonhemopoietic role of EPO and its mechanism(s) of action which may lead to a better understanding of its potential therapeutic value in diverse clinical settings.

show abstract

Effects of darbepoetin α on right and left ventricular systolic and diastolic function in anemic patients with chronic heart failure secondary to ischemic or idiopathic dilated cardiomyopathy

Cited by 78 publications

References 32 publications

2013 ACCF/AHA Guideline for the Management of Heart Failure

2013 ACCF/AHA Guideline for the Management of Heart Failure

The Anemia of Heart Failure

Erythropoietin: A Hormone with Multiple Functions

Contact Info

Product

Resources

About